Similar Articles
The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis
Hikmet Saçmacı, Tülin Aktürk, Nermin Tanık
DOI: 10.4274/tnd.2021.50329
Issue: 2021, Volume 27 - Issue 2
1958
1366
Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
Canan Duman İlki, Tuncay Gündüz, Murat Kürtüncü, Zuhal Yapıcı, Serra Sencer, Mefküre Eraksoy
DOI: 10.4274/tnd.2019.77010
Issue: 2020, Volume 26 - Issue 1
0
1131
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Miraç Ayşen Ünsal
DOI: 10.4274/tnd.2019.00187
Issue: 2019, Volume 25 - Issue 1
0
1175
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir
DOI: 10.4274/tnd.62144
Issue: 2017, Volume 23 - Issue 4
0
1033
Weight Loss and Fingolimod
Nefati Kıylıoğlu
DOI: 10.4274/tnd.87528
Issue: 2017, Volume 23 - Issue 4
0
751
Serum Lipid Profiles, Relationship Between Paraoxonase/Arylesterase Activity and High-density Lipoprotein Levels in Patients with Migraine
Yasemin Eren, Ebru Bilge Dirik, Salim Neşelioğlu, Özcan Erel
DOI: 10.4274/tnd.09216
Issue: 2017, Volume 23 - Issue 3
0
782